Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2021-05-03 4:57 pm Sale | 13D | ALIGOS THERAPEUTICS INC ALGS | Versant Venture Capital VI L.P. | 1,943,916 5.1% | -485,979 (-20.00%) | View |
| 2021-04-08 4:31 pm Purchase | 13D | LAVA THERAPEUTICS N V SHS LVTX | Versant Venture Capital VI L.P. | 3,407,157 13.4% | 3,407,157 (New Position) | View |
| 2021-04-05 4:33 pm Unchanged | 13D | OYSTER PT PHARMA INC OYST | Versant Venture Capital VI L.P. | 2,236,888 8.6% | 0 (Unchanged) | View |
| 2021-03-01 5:16 pm Sale | 13D | OYSTER PT PHARMA INC OYST | Versant Venture Capital VI L.P. | 2,236,888 8.6% | -325,000 (-12.69%) | View |
| 2021-02-12 8:41 pm Sale | 13G | AKERO THERAPEUTICS INC AKRO | Versant Venture Capital VI L.P. | 777,727 2.2% | -2,878,858 (-78.73%) | View |
| 2020-12-03 4:47 pm Sale | 13D | BLACK DIAMOND THERAPEUTICS INC BDTX | Versant Venture Capital VI L.P. | 4,328,883 12% | -1,031,634 (-19.25%) | View |
| 2020-11-20 5:32 pm Sale | 13D | BLACK DIAMOND THERAPEUTICS INC BDTX | Versant Venture Capital VI L.P. | 5,360,517 14.9% | -980,734 (-15.47%) | View |
| 2020-10-30 4:25 pm Purchase | 13D | ALIGOS THERAPEUTICS INC ALGS | Versant Venture Capital VI L.P. | 2,429,895 7.2% | 2,429,895 (New Position) | View |
| 2020-09-25 4:37 pm Sale | 13D | BLACK DIAMOND THERAPEUTICS INC BDTX | Versant Venture Capital VI L.P. | 6,341,251 17.7% | -457,424 (-6.73%) | View |
| 2020-08-21 4:19 pm Sale | 13D | BLACK DIAMOND THERAPEUTICS INC BDTX | Versant Venture Capital VI L.P. | 6,798,675 18.9% | -669,608 (-8.97%) | View |
| 2020-07-31 4:26 pm Purchase | 13G | PANDION THERAPEUTICS INC PAND | Versant Venture Capital VI L.P. | 3,176,507 11.1% | 3,176,507 (New Position) | View |
| 2020-03-13 4:52 pm Purchase | 13D | PASSAGE BIO INC PASG | Versant Venture Capital VI L.P. | 4,026,417 9.2% | 4,026,417 (New Position) | View |
| 2020-02-14 11:07 am Sale | 13G | AKERO THERAPEUTICS INC AKRO | Versant Venture Capital VI L.P. | 3,656,585 12.8% | -448,273 (-10.92%) | View |
| 2020-02-13 5:23 pm Purchase | 13D | BLACK DIAMOND THERAPEUTICS INC BDTX | Versant Venture Capital VI L.P. | 7,468,283 20.8% | 7,468,283 (New Position) | View |
| 2019-11-14 2:45 pm Purchase | 13D | OYSTER PT PHARMA INC OYST | Versant Venture Capital VI L.P. | 2,561,888 12.4% | 2,561,888 (New Position) | View |
| 2019-07-05 1:38 pm Purchase | 13G | AKERO THERAPEUTICS INC AKRO | Versant Venture Capital VI L.P. | 4,104,858 14.7% | 4,104,858 (New Position) | View |